Jun 14, 2025, 14:47
Capstan Therapeutics Announced the Successful Dosing of the First Participants in Capstan’s Phase 1 trial
Capstan Therapeutics shared a post on LinkedIn:
“Today, we announced the successful dosing of the first participants in Capstan’s Phase 1 trial of our lead in vivo CAR-T therapy for autoimmune diseases. This milestone marks an important inflection point in Capstan’s four-year journey to establish itself as the leader in the in vivo CAR-T field… and we’re only getting started!
A huge shoutout to our incredible Capstaneers for their tireless efforts in developing a transformational product that has the potential to greatly improve patient outcomes. Your dedication and hard work have made this achievement possible!
Read more about CPTX2309 in our press release.”
Haig Aghajanian, Co-Founder and Head of Research at Capstan Therapeutics, shared a post by Capstan Therapeutics on LinkedIn, adding:
“Very happy to be able to share this. This is a big step toward bringing these potentially transformative therapies to the patients who need them. Congratulations to the dedicated Capstaneers who worked tirelessly to reach this goal, and to my Co-Founders as we see this vision become a reality.”
Proceed to the video attached to the Capstan Therapeutics‘s post.
You Can Also Read CAR T Cell Therapy for Cancer Treatment by OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 14, 2025, 14:44
Jun 14, 2025, 13:51
Jun 14, 2025, 13:45
Jun 14, 2025, 13:44
Jun 14, 2025, 13:07